Search

Search Constraints

You searched for: Author/Creator Leber, Brian

Search Results

1. A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186. Issue 4 (April 2013)

2. A Small-Molecule Inhibitor of Bax and Bak Oligomerization Prevents Genotoxic Cell Death and Promotes Neuroprotection. Issue 4 (20th April 2017)

3. BCR–ABL1 transcript doubling time as a predictor for treatment‐free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phase. (8th September 2021)

4. Cellular Reprogramming Allows Generation of Autologous Hematopoietic Progenitors From AML Patients That Are Devoid of Patient‐Specific Genomic Aberrations. (21st May 2015)

5. Cellular Reprogramming Allows Generation of Autologous Hematopoietic Progenitors From AML Patients That Are Devoid of Patient‐Specific Genomic Aberrations. (June 2015)

7. Gender and BCR‐ABL transcript type are correlated with molecular response to imatinib treatment in patients with chronic myeloid leukemia. (3rd July 2015)

9. How we treat paroxysmal nocturnal hemoglobinuria: A consensus statement of the Canadian PNH Network and review of the national registry. (25th October 2018)

10. Impact of Frailty on Health Care Resource Utilization and Costs of Care in Myelodysplastic Syndromes. Issue 4 (10th April 2023)